Osaka, Japan
Osaka, Japan

Dainippon Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.The original Dainippon Pharmaceuticals was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and buildings let by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi, who were also among the first students trained abroad at government expense.The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to make a loss. in 1898 it was acquired by Osaka Seiyaku .Another origin of the company is Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical . Dainippon and Sumitomo merged on October 1, 2005 to create Dainippon Sumitomo Pharma. As a result Sumitomo Chemical has 50.20% ownership in Dainippon Sumitomo Pharma as of March 31, 2014. Wikipedia.


Time filter

Source Type

Patent
Intercept Pharmaceuticals and Dainippon Sumitomo | Date: 2016-04-26

The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.


Patent
Sapporo Medical University and Dainippon Sumitomo | Date: 2017-01-18

A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.


Patent
Dainippon Sumitomo | Date: 2016-12-30

The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R^(1a), R^(1b), R^(1c )and R^(1d )are hydrogen, halogen, cyano, C_(1-4 )alkyl, C_(1-4 )alkoxy, or the like, provided that at least one of R^(1a), R^(1b), R^(1c )and R^(1d )is C_(6-10 )aryl, C_(6-10 )aryloxy, or the like, R^(2 )and R^(3 )are hydrogen, C_(1-6 )alkyl, C_(3-10 )cycloalkyl, or the like, R^(4 )is hydrogen, C_(1-6 )alkyl, C_(3-7 )cycloalkyl, or the like, m is 1, 2 or 3, L is CR^(7)R^(8), and R^(7 )and R^(8 )are hydrogen, hydroxyl, C_(1-4 )alkyl, C_(1-4 )alkoxy, or the like.


Patent
Sapporo Medical University and Dainippon Sumitomo | Date: 2016-05-24

A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.


Patent
Dainippon Sumitomo and Sapporo Medical University | Date: 2016-08-10

The purpose of the present invention is to provide: a detection agent for specifically detecting cancer stem cells; a tumor antigen peptide specifically exhibited by cancer stem cells; a pharmaceutical composition for the prevention and/or treatment of cancer, containing same as an effective component thereof; and a method for screening said tumor antigen peptide. A peptide indicated by YO-XO-ZO, a polyepitope peptide including at least one said peptide as an epitope peptide and having a plurality of epitope peptides joined therein, a polynucleotide that codes at least either the peptide or the polyepitope peptide, a pharmaceutical composition containing these as an effective component thereof, and a cancer prevention and/or treatment agent characterized by inducing CTLs.


Patent
Dainippon Sumitomo and Astrazeneca | Date: 2016-05-11

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.


Patent
Dainippon Sumitomo | Date: 2016-03-04

A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): wherein A is CR^(1E )or a nitrogen atom, XYZ is NCONR^(3A)R^(3B )and the like, R^(1A )to R^(1E )are each independently a hydrogen atom and the like, R^(2A )to R^(2D )are each independently a hydrogen atom and the like, R^(3A )and R^(3B )are each independently an optionally-substituted C_(3-10 )cycloalkyl and the like, and n is 1 or 2or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of 7 nicotinic acetylcholine receptor (7 nAChR).


Patent
Sumitomo Chemical and Dainippon Sumitomo | Date: 2016-07-20

The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt:^(1) represents optionally substituted C_(1-4) alkyl, n shows integer of 1 to 4, R^(2) represents optionally substituted C_(1-4) alkyl or hydrogen atom, R^(3) represents optionally substituted C_(1-4) alkyl, R^(4a), R^(4b), R^(4c), and R^(4d), similarly or differently, represent optionally substituted C_(6-14) aryl, optionally substituted C_(1-4) alkyl, or hydrogen atom and the like, A represents optionally substituted C_(6-14) aryl or optionally substituted 5 to 11 membered heteroaryl].


Patent
Dainippon Sumitomo | Date: 2016-01-13

The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D_(4 )receptor agonist.


Patent
Dainippon Sumitomo | Date: 2016-04-13

The present invention provides a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof with high selectivity for dopamine D_(4) receptors, which are useful for treating a disease such as attention deficit hyperactivity disorder. Specifically, a compound of formula (1) or a pharmaceutically acceptable salt thereof is provided, wherein n and m are independently 1 or 2; R^(a) is C_(1-6) alkyl group, C_(3-6) cycloalkyl group, or amino group; R^(b) is hydrogen atom, C_(1-6) alkyl group or the like, provided that when R^(a) is amino group, then R^(b) is hydrogen atom; R^(c1) and R^(c2) are independently hydrogen atom, or C_(1-6) alkyl group; R^(d1) and R^(d2) are independently hydrogen atom, fluorine atom or the like; ring Q is an optionally-substituted pyridyl group or an optionally-substituted isoquinolyl group; and the bond having a dashed line is a single or double bond.

Loading Dainippon Sumitomo collaborators
Loading Dainippon Sumitomo collaborators